A recalled sickle cell drug is drawing new scrutiny from attorneys who say it may have done more harm than good, possibly ...

Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

Pfizer has withdrawn Oxbryta from global markets and halted all clinical trials, citing safety concerns following clinical data that raised issues about fatal complications in sickle cell disease ...

Oxbryta is a prescription drug used to treat sickle cell disease. Learn about the common, mild, and serious side effects it can cause and how to manage them.

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.

Pfizer PFE announced that it is voluntarily withdrawing all lots of its sickle-cell disease (SCD) medication Oxbryta (voxelotor) from all markets where the drug is approved.

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

Pfizer has made the decision to withdraw Oxbryta (voxelotor), a treatment for sickle cell disease, from all markets where it is approved.

Pfizer Voluntarily Withdraws Sickle Cell Disease Treatment Oxbryta From Global Market Due To Painful Disease Complication, Deaths (UPDATED) Vandana Singh Thu, Sep 26, 2024, 10:28 AM2 min read ...

Risks and uncertainties include, among other things, uncertainties regarding the future of OXBRYTA (voxelotor), as well as uncertainties related to other sickle cell disease assets in our ...

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® for the treatment of sickle cell disease at this time, in all markets where it is approved. Pfizer is also ...

Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease ( ...